| Bendamustine studied in …STUDIED_INderived200 of 282show all (up to 200) |
|---|
| → studied in | NCT06846671Phase 3 · recruiting A Study of Tacabrutideg (BGB-16673) Compared to Investigator's Choice in Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both Bruton Tyrosine Kinase (BTK) and B-cell Leukemia/Lymphoma 2 Protein (BCL2) Inhibitors · 282 trials list this drug (72 active) | — | — | Chronic Lymphocytic Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05023980Phase 3 · active not recruiting A Study of Pirtobrutinib (LOXO-305) Versus Bendamustine Plus Rituximab (BR) in Untreated Patients With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) · 282 trials list this drug (72 active) | — | — | Chronic Lymphocytic Leukemia,Small Lymphocytic Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05139017Phase 2/Phase 3 · recruiting A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003) · 282 trials list this drug (72 active) | — | — | Diffuse Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07634471Phase 2/Phase 3 · recruiting A Clinical Trial of MK-1045 and Rituximab in People With Follicular Lymphoma (MK-1045-007) · 282 trials list this drug (72 active) | — | — | Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04083495Phase 2 · recruiting CD30 CAR for Relapsed/Refractory CD30+ T Cell Lymphoma · 282 trials list this drug (72 active) | — | — | Peripheral T-Cell Lymphoma, Not Otherwise Specified | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04115631Phase 2 · active not recruiting A Comparison of Three Chemotherapy Regimens for the Treatment of Patients With Newly Diagnosed Mantle Cell Lymphoma · 282 trials list this drug (72 active) | — | — | Liver Lymphoma,Mantle Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06091254Phase 3 · recruiting A Trial to Learn if Odronextamab is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Different Types of Chemotherapy for Adult Participants With Previously Untreated Follicular Lymphoma · 282 trials list this drug (72 active) | — | — | Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04624906Phase 2 · active not recruiting Bendamustine, Rituximab and Acalabrutinib in Waldenstrom's Macroglobulinemia · 282 trials list this drug (72 active) | — | — | Waldenstrom Macroglobulinemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06084936Phase 3 · recruiting A Study to Evaluate Glofitamab as a Single Agent vs. Investigator's Choice in Participants With Relapsed/Refractory Mantle Cell Lymphoma · 282 trials list this drug (72 active) | — | — | Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05508867Phase 2 · completed A Study of Coformulated Favezelimab/Pembrolizumab (MK-4280A) Versus Physician's Choice Chemotherapy in PD-(L)1-refractory, Relapsed or Refractory Classical Hodgkin Lymphoma (MK-4280A-008) · 282 trials list this drug (72 active) | — | — | Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06561347Phase 2 · recruiting Zanubrutinib, Bendamustine, Rituximab Prev. Untreated WM · 282 trials list this drug (72 active) | — | — | Waldenstrom Macroglobulinemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01886872Phase 3 · active not recruiting Rituximab and Bendamustine Hydrochloride, Rituximab and Ibrutinib, or Ibrutinib Alone in Treating Older Patients With Previously Untreated Chronic Lymphocytic Leukemia · 282 trials list this drug (72 active) | — | — | Chronic Lymphocytic Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06970743Phase 3 · active not recruiting A Study of BGB-16673 Compared to Investigator's Choice in Participants With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Covalent Bruton Tyrosine Kinase (BTK) Inhibitors · 282 trials list this drug (72 active) | — | — | Chronic Lymphocytic Leukemia,Small Lymphocytic Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04515238Phase 2 · active not recruiting Sequential Regimen of Bendamustine Followed by Obinutuzumab (GA101), Zanubrutinib (BGB-3111) and Venetoclax (ABT-199) in Patients With Relapsed/Refractory CLL · 282 trials list this drug (72 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07753369Phase 3 · not yet recruiting A Clinical Trial to Evaluate the Efficacy and Safety of TQB3909 Tablets Versus Investigator's Choice in the Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) · 282 trials list this drug (72 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06191744Phase 3 · active not recruiting Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular Lymphoma · 282 trials list this drug (72 active) | — | — | Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03696784Phase 1 · active not recruiting Anti-CD19 CAR-T Cells With Inducible Caspase 9 Safety Switch for B-cell Lymphoma · 282 trials list this drug (72 active) | — | — | B-Cell Malignant Neoplasm,Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06425302Phase 2 · active not recruiting A Study to Evaluate the Efficacy and Safety of Golcadomide in Combination With Rituximab in Participants With Newly Diagnosed Advanced Stage Follicular Lymphoma · 282 trials list this drug (72 active) | — | — | Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02970318Phase 3 · active not recruiting A Study of Acalabrutinib vs Investigator's Choice of Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in R/R CLL · 282 trials list this drug (72 active) | — | — | Chronic Lymphocytic Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01059786Phase 2 · active not recruiting Randomized Phase II Trial of Rituximab With Either Pentostatin or Bendamustine for Multiply Relapsed or Refractory Hairy Cell Leukemia · 282 trials list this drug (72 active) | — | — | Hairy Cell Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01479842Phase 1 · active not recruiting Rituxan/Bendamustine/PCI-32765 in Relapsed DLBCL, MCL, or Indolent Non-Hodgkin's Lymphoma · 282 trials list this drug (72 active) | — | — | Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue,Grade 3 Follicular Lymphoma,Mantle Cell Lymphoma+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07719855Phase 3 · not yet recruiting A Multicenter, Prospective, Open-Label, Randomized Controlled Clinical Study of Orelabrutinib Combined With Obinutuzumab and Lenalidomide Versus Obinutuzumab Plus Chemotherapy for Treatment-Naive Follicular Lymphoma · 282 trials list this drug (72 active) | — | — | Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04022239Phase 1/Phase 2 · recruiting Bendamustine With or Without Cyclophosphamide in Preventing GVHD in Patients Undergoing Stem Cell Transplant · 282 trials list this drug (72 active) | — | — | Hematopoietic and Lymphatic System Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04792489Phase 2 · recruiting DALY II USA/ MB-CART2019.1 for DLBCL · 282 trials list this drug (72 active) | — | — | Central Nervous System Lymphoma,Transformed Non-Hodgkin Lymphoma,Diffuse Large B-Cell Lymphoma+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05451771Phase 1/Phase 2 · active not recruiting Venetoclax-Dexamethasone in Relapsed and/or Refractory t(11;14) Amyloidosis · 282 trials list this drug (72 active) | — | — | AL Amyloidosis | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03269669Phase 2 · active not recruiting Obinutuzumab With or Without Umbralisib, Lenalidomide, or Combination Chemotherapy in Treating Patients With Relapsed or Refractory Grade I-IIIa Follicular Lymphoma · 282 trials list this drug (72 active) | — | — | Follicular Lymphoma,Grade 1 Follicular Lymphoma,Grade 2 Follicular Lymphoma+1 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06043713Phase 1 · recruiting Autologous CD8+ and CD4+ Transgenic T Cells Expressing High Affinity KRASG12V Mutation-Specific T Cell Receptors (FH-A11KRASG12V-TCR) in Treating Patients With Metastatic Solid Tumor Cancers With KRAS G12V Mutations · 282 trials list this drug (72 active) | — | — | Malignant Solid Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04809766Phase 1 · terminated Mesothelin-Specific T-Cells (FH-TCR-Tᴍsʟɴ) for the Treatment of Metastatic Pancreatic Ductal Adenocarcinoma · 282 trials list this drug (72 active) | — | — | Malignant Pancreatic Neoplasm,Pancreatic Ductal Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04587687Phase 2 · recruiting Brentuximab Vedotin and Bendamustine for the Treatment of Relapsed or Refractory Follicular Lymphoma · 282 trials list this drug (72 active) | — | — | Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01657331Phase 1/Phase 2 · completed Brentuximab Vedotin and Bendamustine for the Treatment of Hodgkin Lymphoma and Anaplastic Large Cell Lymphoma (ALCL) · 282 trials list this drug (72 active) | — | — | Anaplastic Large Cell Lymphoma,Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03872180Phase 2 · active not recruiting Bendamustine, Obinutuzumab, and Venetoclax in Patients With Untreated Mantle Cell Lymphoma · 282 trials list this drug (72 active) | — | — | Mantle Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04510636Phase 2 · recruiting Study of Pembrolizumab With Bendamustine in Hodgkin Lymphoma · 282 trials list this drug (72 active) | — | — | Malignant Neoplasm,Classic Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03755804Phase 2 · active not recruiting Pediatric Classical Hodgkin Lymphoma Consortium Study: cHOD17 · 282 trials list this drug (72 active) | — | — | Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06006117Phase 3 · recruiting Mosunetuzumab-Lenalidomide Versus Investigator Choices in Patients With Relapsed or Refractory Marginal Zone Lymphoma · 282 trials list this drug (72 active) | — | — | Marginal Zone Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03602157Phase 1 · active not recruiting Study of CAR-T Cells Expressing CD30 and CCR4 for r/r CD30+ HL and CTCL · 282 trials list this drug (72 active) | — | — | Neoplasm,Lymphoma,Cutaneous Lymphoma+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04892277Phase 1 · recruiting CD19-Directed CAR-T Cell Therapy for the Treatment of Relapsed/Refractory B Cell Malignancies · 282 trials list this drug (72 active) | — | — | B-Cell Non-Hodgkin Lymphoma,Chronic Lymphocytic Leukemia,Small Lymphocytic Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01661881Phase 2 · active not recruiting Rituximab/Bendamustine + Rituximab/Cytarabine for Mantle Cell Lymphoma · 282 trials list this drug (72 active) | — | — | Mantle Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01415752Phase 2 · active not recruiting Rituximab, Bendamustine Hydrochloride, and Bortezomib Followed by Rituximab and Lenalidomide in Treating Older Patients With Previously Untreated Mantle Cell Lymphoma · 282 trials list this drug (72 active) | — | — | Lymphoma,Mantle Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07139873Phase 3 · recruiting A Study of DZD8586 Versus Investigator's Choice in r/r CLL/SLL (TAI-SHAN6) · 282 trials list this drug (72 active) | — | — | Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02972840Phase 3 · active not recruiting A Study of BR Alone Versus in Combination With Acalabrutinib in Subjects With Previously Untreated MCL · 282 trials list this drug (72 active) | — | — | Mantle Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06911502Phase 3 · recruiting A Study to Compare the Efficacy and Safety of Golcadomide in Combination With Rituximab (Golca + R) vs Investigator's Choice in Participants With Relapsed/Refractory Follicular Lymphoma Who Have Received at Least 1 Prior Line of Systemic Therapy (GOLSEEK-4) · 282 trials list this drug (72 active) | — | — | Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04002297Phase 3 · active not recruiting A Study to Investigate the Efficacy of Zanubrutinib Plus Rituximab Compared With Bendamustine Plus Rituximab in Adults With Previously Untreated Mantle Cell Lymphoma Who Are Ineligible for Stem Cell Transplantation · 282 trials list this drug (72 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07593482Phase 2 · not yet recruiting Bendamustine Versus Fludarabine/Cyclophosphamide for Lymphodepletion in Chimeric Antigen Receptor T-cell Immunotherapy (CAR-T): a Randomized Trial. · 282 trials list this drug (72 active) | — | — | B-Cell Malignant Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07225985Phase 1/Phase 2 · recruiting Pralatrexate With Bendamustine and Total-Body Irradiation Followed by Donor Stem Cell Transplant for the Treatment of Relapsed or Refractory T-Cell Non-Hodgkin Lymphoma · 282 trials list this drug (72 active) | — | — | T-Cell Non-Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05848765Phase 2 · recruiting Relapsed Follicular Lymphoma Randomised Trial Against Standard ChemoTherapy · 282 trials list this drug (72 active) | — | — | Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04666038Phase 3 · active not recruiting Study of LOXO-305 (Pirtobrutinib) Versus Investigator's Choice (Idelalisib Plus Rituximab or Bendamustine Plus Rituximab) in Patients With Previously Treated Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) · 282 trials list this drug (72 active) | — | — | Chronic Lymphocytic Leukemia,Small Lymphocytic Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03593018Phase 3 · completed Efficacy and Safety of Oral Azacitidine Compared to Investigator's Choice Therapy in Patients With Relapsed or Refractory AITL · 282 trials list this drug (72 active) | — | — | Follicular Helper T-Cell Lymphoma, Angioimmunoblastic-Type | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03623373Phase 2 · completed Acalabrutinib With Bendamustine / Rituximab Followed by Cytarabine / Rituximab for Untreated Mantle Cell Lymphoma · 282 trials list this drug (72 active) | — | — | Mantle Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03856216Phase 2 · terminated Inotuzumab Ozogamicin and Chemotherapy in Treating Patients With Leukemia or Lymphoma Undergoing Stem Cell Transplantation · 282 trials list this drug (72 active) | — | — | Lymphocytic Neoplasm,Lymphoma,Acute Lymphoblastic Leukemia+1 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06522737Phase 3 · recruiting A Study of Duvelisib Versus Gemcitabine or Bendamustine in Participants With Relapsed/Refractory Nodal T Cell Lymphoma With T Follicular Helper (TFH) Phenotype · 282 trials list this drug (72 active) | — | — | Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04673617Phase 1/Phase 2 · completed AB-101 as Monotherapy and With Immunotherapy in Patients With Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma · 282 trials list this drug (72 active) | — | — | Non-Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04629729Phase 1 · active not recruiting FT819 in Subjects With B-cell Malignancies · 282 trials list this drug (72 active) | — | — | B-Cell Malignant Neoplasm,Chronic Lymphocytic Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06313996Phase 3 · withdrawn A Study to Evaluate the Efficacy and Safety of Liso-cel Compared to Standard of Care in Adults With Relapsed or Refractory Follicular Lymphoma · 282 trials list this drug (72 active) | — | — | Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05624554Phase 3 · active not recruiting A Study of Nemtabrutinib vs Chemoimmunotherapy for Participants With Previously Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Without TP53 Aberrations (MK-1026-008, BELLWAVE-008) · 282 trials list this drug (72 active) | — | — | Chronic Lymphocytic Leukemia,Small Lymphocytic Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06483048Phase 1 · recruiting MUC1-Activated T Cells for the Treatment of Relapsed and Resistant Ovarian Cancer · 282 trials list this drug (72 active) | — | — | Primary Peritoneal Carcinoma,Fallopian Tube Malignant Mixed Mesodermal (Mullerian) Tumor,Female Reproductive System Carcinoma+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03336333Phase 3 · active not recruiting A Study Comparing Zanubrutinib With Bendamustine Plus Rituximab in Participants With Previously Untreated CLL or SLL · 282 trials list this drug (72 active) | — | — | Chronic Lymphocytic Leukemia,Small Lymphocytic Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04285567Phase 3 · completed A Study to Compare the Efficacy and Safety of a Combined Regimen of Venetoclax and Obinutuzumab Versus Fludarabine, Cyclophosphamide, and Rituximab (FCR)/ Bendamustine And Rituximab (BR) in FIT Patients With Previously Untreated Chronic Lymphocytic Leukemia (CLL) Without DEL (17P) or TP53 Mutation · 282 trials list this drug (72 active) | — | — | Chronic Lymphocytic Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03609593Phase 2 · completed Bendamustine/Rituximab Followed by Venetoclax and Rituximab for Treatment of Chronic Lymphocytic Leukemia · 282 trials list this drug (72 active) | — | — | Chronic Lymphocytic Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06854003Phase 2 · recruiting BRAZAN: A Randomized Phase 2 Study of Bendamustine, Rituximab, Cytarabine (AraC) Induction With Zanubrutinib (BRAZAN) Followed by Zanubrutinib/Rituximab +/- Sonrotoclax Maintenance in Treatment-Naïve Mantle Cell Lymphoma · 282 trials list this drug (72 active) | — | — | Lymphoma,Mantle Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05551936Phase 1/Phase 2 · active not recruiting A Study of Tazemetostat With Rituximab and Abbreviated Bendamustine in the Frontline Treatment of High Tumor Burden Follicular Lymphoma · 282 trials list this drug (72 active) | — | — | Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06191887Phase 1 · recruiting B-Cell Activating Factor Receptor (BAFFR)-Based Chimeric Antigen Receptor T-Cells With Fludarabine and Cyclophosphamide Lymphodepletion for the Treatment of Relapsed or Refractory B-cell Hematologic Malignancies · 282 trials list this drug (72 active) | — | — | B-Cell Non-Hodgkin Lymphoma,Chronic Lymphocytic Leukemia,Small Lymphocytic Lymphoma+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04674813Phase 1 · completed A Study of CC-95266 in Participants With Relapsed and/or Refractory Multiple Myeloma · 282 trials list this drug (72 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04223765Phase 1 · recruiting Study of Kappa Chimeric Antigen Receptor (CAR) T Lymphocytes Co-Expressing the Kappa and CD28 CARs for Relapsed/Refractory Kappa+ Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma. · 282 trials list this drug (72 active) | — | — | Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue,Follicular Lymphoma,Indolent Non-Hodgkin Lymphoma+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07189065Phase 2 · recruiting A Study of Rocbrutinib in Participants With Relapse or Refractory Non-GCB Diffuse Large B-Cell Lymphoma · 282 trials list this drug (72 active) | — | — | Diffuse Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05182073Phase 1 · completed FT576 in Subjects With Multiple Myeloma · 282 trials list this drug (72 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06241456Phase 1 · recruiting FT825/ONO-8250, an Off-the-Shelf, HER2 CAR-T, With or Without Monoclonal Antibodies in Advanced Solid Tumors · 282 trials list this drug (72 active) | — | — | Solid Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03352765Phase 1 · active not recruiting A Phase I Study of Bendamustine and Melphalan Conditioning and Autologous Stem Cell Transplantation for Treatment of Multiple Myeloma and Relapsed/Refractory B-cell Lymphoma in Elderly Patients · 282 trials list this drug (72 active) | — | — | Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01286272Phase 2 · completed Ofatumumab and Bendamustine Hydrochloride With or Without Bortezomib in Treating Patients With Untreated Follicular Non-Hodgkin Lymphoma · 282 trials list this drug (72 active) | — | — | Grade 3a Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02996773Phase 1 · completed Haploidentical BMT With Post-Transplant Cyclophosphamide and Bendamustine · 282 trials list this drug (72 active) | — | — | Acute Lymphoblastic Leukemia,Hodgkin Lymphoma,Myelodysplastic Syndrome+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02315157Phase 1 · withdrawn Bendamustine Hydrochloride in Treating Patients With Previously Treated Multiple Myeloma · 282 trials list this drug (72 active) | — | — | Multiple Myeloma,Plasma Cell Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05371093Phase 3 · active not recruiting Study of Axicabtagene Ciloleucel Versus Standard of Care Therapy in Participants With Relapsed/Refractory Follicular Lymphoma · 282 trials list this drug (72 active) | — | — | Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02153580Phase 1 · active not recruiting Cellular Immunotherapy Following Chemotherapy in Treating Patients With Recurrent Non-Hodgkin Lymphomas, Chronic Lymphocytic Leukemia, or B-Cell Prolymphocytic Leukemia · 282 trials list this drug (72 active) | — | — | B-Cell Prolymphocytic Leukemia,Hairy Cell Leukemia,Chronic Lymphocytic Leukemia+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04607772Phase 1/Phase 2 · withdrawn Study of Selinexor in Combination With Backbone Treatments or Novel Therapies In Participants With Relapsed or Refractory (RR) Diffuse Large B-Cell Lymphoma (DLBCL) · 282 trials list this drug (72 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07169565Phase 1 · not yet recruiting Ibrutinib Followed by BR (Bendamustine and Rituximab) as a Time-Limited Therapy for Waldenström Macroglobulinemia · 282 trials list this drug (72 active) | — | — | Waldenstrom Macroglobulinemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05950334Phase 1 · completed FT522 With Rituximab in Relapsed/Refractory B-Cell Lymphoma (FT522-101) · 282 trials list this drug (72 active) | — | — | B-Cell Malignant Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03424122Phase 1 · completed INCB050465 in Combination With Rituximab, Bendamustine and Rituximab, or Ibrutinib in Participants With Previously Treated B-Cell Lymphoma (CITADEL-112) · 282 trials list this drug (72 active) | — | — | B-Cell Malignant Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03834688Phase 2 · completed Phase II Study of Bendamustine and Rituximab Plus Venetoclax in Untreated Mantle Cell Lymphoma Over 60 Years of Age · 282 trials list this drug (72 active) | — | — | Mantle Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03739619Phase 1/Phase 2 · completed Gemcitabine, Bendamustine, and Nivolumab in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma · 282 trials list this drug (72 active) | — | — | Hodgkin Lymphoma,Classic Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02763319Phase 2/Phase 3 · completed A Trial to Evaluate the Efficacy and Safety of Tafasitamab With Bendamustine (BEN) Versus Rituximab (RTX) With BEN in Adult Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL) · 282 trials list this drug (72 active) | — | — | Diffuse Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01776840Phase 3 · completed A Study of the Bruton's Tyrosine Kinase Inhibitor Ibrutinib Given in Combination With Bendamustine and Rituximab in Patients With Newly Diagnosed Mantle Cell Lymphoma · 282 trials list this drug (72 active) | — | — | Mantle Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07003464Phase 2 · not yet recruiting Phase II Trial of Zanubrutinib, Obinutuzumab, Bendamustine (ZGB) as First-Line Therapy for Chronic Lymphocytic Leukemia: A Single-Center Study · 282 trials list this drug (72 active) | — | — | Chronic Lymphocytic Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01974440Phase 3 · completed A Study of PCI-32765 (Ibrutinib) in Combination With Either Bendamustine and Rituximab or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Participants With Previously Treated Indolent Non-Hodgkin Lymphoma · 282 trials list this drug (72 active) | — | — | Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06961500Phase 2 · not yet recruiting Obinutuzumab With CHOP Versus Obinutuzumab With Bendamustine in the Treatment of Newly Diagnosed Follicular Lymphoma Grade 3A · 282 trials list this drug (72 active) | — | — | Grade 3a Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04217317Phase 2 · terminated CPI-613 in Combination With Bendamustine in Patients With Relapsed/Refractory T-Cell Non-Hodgkin Lymphoma · 282 trials list this drug (72 active) | — | — | Non-Hodgkin Lymphoma,T-Cell Non-Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01458366Phase 1/Phase 2 · completed Phase I/II Study of Bendamustine in Combination With Ofatumumab, Carboplatin and Etoposide · 282 trials list this drug (72 active) | — | — | Non-Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02224729Phase 2 · completed Bendamustine Hydrochloride, Bortezomib, and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma · 282 trials list this drug (72 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01352312Phase 1 · terminated Combination of Pentostatin, Bendamustine and Ofatumumab for Treatment of Chronic Lymphocytic Leukemia and Lymphoma · 282 trials list this drug (72 active) | — | — | B-Cell Non-Hodgkin Lymphoma,Chronic Lymphocytic Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06094842Phase 1 · withdrawn Autologous T Cells Lentivirally Transduced to Express L1CAM-Specific Chimeric Antigen Receptors in Treating Patients With Locally Advanced and Unresectable or Metastatic Small Cell Neuroendocrine Prostate Cancer · 282 trials list this drug (72 active) | — | — | Malignant Prostate Neoplasm,Prostate Carcinoma,Prostate Small Cell Neuroendocrine Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02927769Phase 2 · completed A Study of Nivolumab Plus Brentuximab Vedotin in Patients Between 5 and 30 Years Old, With Hodgkin's Lymphoma (cHL), Relapsed or Refractory From First Line Treatment · 282 trials list this drug (72 active) | — | — | Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03187223Phase 2 · completed Bendamustine and Melphalan in Myeloma · 282 trials list this drug (72 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03615664Phase 2 · completed The Efficacy of Salvage BGD With autoSCT Consolidation in Advanced Classical HL Patients Not Responding to ABVD · 282 trials list this drug (72 active) | — | — | Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06761911Phase 4 · not yet recruiting BV in the Treatment of Relapsed/refractory Hodgkin Lymphoma · 282 trials list this drug (72 active) | — | — | Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06557330Phase 2 · not yet recruiting MRD Guided De-intensification of Bendamustine/Rituximab for Indolent Non-Hodgkin Lymphoma · 282 trials list this drug (72 active) | — | — | Lymphoma,Indolent Non-Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06757894Phase 2 · not yet recruiting Efficacy and Safety of Zuberitamab Combined with Bendamustine, Followed by Monotherapy Maintenance, in Treatment-naïve Follicular Lymphoma · 282 trials list this drug (72 active) | — | — | Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00769522Phase 3 · completed FCR or BR in Patients With Previously Untreated B-Cell Chronic Lymphocytic Leukemia · 282 trials list this drug (72 active) | — | — | Chronic Lymphocytic Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02950051Phase 3 · completed Standard Chemoimmunotherapy (FCR/BR) Versus Rituximab + Venetoclax (RVe) Versus Obinutuzumab (GA101) + Venetoclax (GVe) Versus Obinutuzumab + Ibrutinib + Venetoclax (GIVe) in Fit Patients With Previously Untreated Chronic Lymphocytic Leukemia (CLL) Without Del(17p) or TP53 Mutation · 282 trials list this drug (72 active) | — | — | Chronic Lymphocytic Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03787264Phase 2 · completed Sequential Regimen of Bendamustin-Debulking Followed by Obinutuzumab, Acalabrutinib and Venetoclax in Patients With Relapsed/Refractory CLL · 282 trials list this drug (72 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06363994Phase 3 · recruiting A Global Phase 3 Study of Orelabrutinib+BR Vs.BR in Pts with TN MCL · 282 trials list this drug (72 active) | — | — | Mantle Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02626455Phase 3 · terminated Study of Copanlisib in Combination With Standard Immunochemotherapy in Relapsed Indolent Non-Hodgkin's Lymphoma (iNHL) · 282 trials list this drug (72 active) | — | — | Non-Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03524235Phase 1 · completed Haploidentical Stem Cell Transplant with Prophylactic Natural Killer DLI for Lymphoma, Multiple Myeloma, and CLL · 282 trials list this drug (72 active) | — | — | Lymphoma,Hodgkin Lymphoma,Multiple Myeloma+1 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04745832Phase 3 · terminated Phase 3 Study of Zandelisib (ME-401) in Combination With Rituximab in Patients With iNHL - (COASTAL) · 282 trials list this drug (72 active) | — | — | Non-Hodgkin Lymphoma,Follicular Lymphoma,Marginal Zone Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03311126Phase 2 · terminated Bendamustine + Obinutuzumab Induction With Obinutuzumab Maintenance in Untreated Mantle Cell Lymphoma · 282 trials list this drug (72 active) | — | — | Non-Hodgkin Lymphoma,Mantle Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04943757Phase 2 · completed Post-transplantation Benadamustine and Cyclophosphamide in Patients With Refractory Myeloid Malignancies · 282 trials list this drug (72 active) | — | — | Myelodysplastic Syndrome,Myeloproliferative Neoplasm,Acute Myeloid Leukemia+1 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02002598Phase 1/Phase 2 · terminated Carfilzomib With Bendamustine and Dexamethasone in Multiple Myeloma · 282 trials list this drug (72 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00991211Phase 3 · completed Bendamustine Plus Rituximab Versus CHOP Plus Rituximab · 282 trials list this drug (72 active) | — | — | Non-Hodgkin Lymphoma,Chronic Lymphocytic Leukemia,Follicular Lymphoma+1 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06554600Phase 2 · recruiting A Study of Zanubrutinib in Combination With Polatuzumab Vedotin, Bendamustine and Rituximab in the Treatment of Relapsed/Refractory Diffuse Large B-cell Lymphoma · 282 trials list this drug (72 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03406156Phase 3 · completed A Study in Previously Untreated Chronic Lymphocytic Leukemia (CLL) Subjects, Excluding Those With the 17p Deletion, to Evaluate Debulking Regimens Prior to Initiating Venetoclax Combination Therapy · 282 trials list this drug (72 active) | — | — | Chronic Lymphocytic Leukemia,Small Lymphocytic Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01664910Phase 1/Phase 2 · completed CMC-544 and Allogeneic Transplantation for CD22 Positive-Lymphoid Malignancies · 282 trials list this drug (72 active) | — | — | Hematopoietic and Lymphoid Cell Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06496308Phase 3 · recruiting Bendamustine and Rituximab With or Without Orelabrutinib in MCL Treatment · 282 trials list this drug (72 active) | — | — | Mantle Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06477549Phase 2 · recruiting BeFluBu vs FluBuRux Conditioning in Haploidentical HCT · 282 trials list this drug (72 active) | — | — | Acute Lymphoblastic Leukemia,Lymphoblastic Lymphoma,Myelodysplastic Syndrome+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06465446Phase 3 · not yet recruiting A Study of IMM01 Plus Tiselizumab Versus Physician's Choice Chemotherapy in PD(L)1-refractory Classical Hodgkin Lymphoma · 282 trials list this drug (72 active) | — | — | Classic Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01716806Phase 2 · completed A Study of Brentuximab Vedotin With Hodgkin Lymphoma (HL) and CD30-expressing Peripheral T-cell Lymphoma (PTCL) · 282 trials list this drug (72 active) | — | — | Hodgkin Lymphoma,Peripheral T-Cell Lymphoma, Not Otherwise Specified | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02348216Phase 1/Phase 2 · completed Study Evaluating the Safety and Efficacy of KTE-C19 in Adult Participants With Refractory Aggressive Non-Hodgkin Lymphoma · 282 trials list this drug (72 active) | — | — | Diffuse Large B-Cell Lymphoma,Primary Mediastinal Large B-Cell Lymphoma,High Grade B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04942730Phase 2 · completed Benadamustine, Fludarabine and Busulfan Conditioning in Recipients of Haploidentical Stem Cell Transplantation (FluBuBe) · 282 trials list this drug (72 active) | — | — | Acute Lymphoblastic Leukemia,Lymphoblastic Lymphoma,Myelodysplastic Syndrome+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03817853Phase 4 · completed An Open-Label, Single Arm Study of Obinutuzumab Short Duration Infusion in Patients With Previously Untreated Advanced Follicular Lymphoma · 282 trials list this drug (72 active) | — | — | Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06205290Phase 3 · withdrawn A Study to Compare the Efficacy and Safety of Lisocabtagene Maraleucel vs Investigator's Choice Options in Adult Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma, Whose Disease Has Failed Treatment With Both BTKi and BCL2i Therapies · 282 trials list this drug (72 active) | — | — | Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05711628Phase 3 · withdrawn A Trial Comparing Chemotherapy Versus Novel Immune Checkpoint Inhibitor (Pembrolizumab) Plus Chemotherapy in Treating Relapsed/Refractory Classical Hodgkin Lymphoma · 282 trials list this drug (72 active) | — | — | Classic Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04083898Phase 1 · terminated Isatuximab, Bendamustine, and Prednisone in Refractory Multiple Myeloma · 282 trials list this drug (72 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01754402Phase 1/Phase 2 · unknown Bendamustine + Pomalidomide + Dex in R/R Multiple Myeloma · 282 trials list this drug (72 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02168140Phase 1 · completed CPI-613 and Bendamustine Hydrochloride in Treating Patients With Relapsed or Refractory T-Cell Non-Hodgkin Lymphoma or Hodgkin Lymphoma · 282 trials list this drug (72 active) | — | — | Anaplastic Large Cell Lymphoma,Adult Acute Lymphoblastic Leukemia,Adult Hodgkin Lymphoma+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02733042Phase 1/Phase 2 · completed A Study to Determine Dose, Safety, and Efficacy of Durvalumab as Monotherapy and in Combination Therapy in Subjects With Lymphoma or Chronic Lymphocytic Leukemia · 282 trials list this drug (72 active) | — | — | Leukemia,Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02728531Phase 1 · completed Bendamustine and Rituximab Alternating With Cytarabine and Rituximab for Untreated Mantle Cell Lymphoma · 282 trials list this drug (72 active) | — | — | Mantle Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04023071Phase 1 · terminated FT516 in Subjects With Advanced Hematologic Malignancies · 282 trials list this drug (72 active) | — | — | B-Cell Malignant Neoplasm,Acute Myeloid Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04245722Phase 1 · terminated FT596 as a Monotherapy and in Combination With Anti-CD20 Monoclonal Antibodies · 282 trials list this drug (72 active) | — | — | B-Cell Malignant Neoplasm,Chronic Lymphocytic Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02005471Phase 3 · completed A Study to Evaluate the Benefit of Venetoclax Plus Rituximab Compared With Bendamustine Plus Rituximab in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) · 282 trials list this drug (72 active) | — | — | Chronic Lymphocytic Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01177683Phase 1/Phase 2 · terminated Bendamustine in Combination With Bortezomib and Pegylated Liposomal Doxorubicin for Multiple Myeloma · 282 trials list this drug (72 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05979948Phase 2 · unknown A Phase 2 Clinical Trial to Evaluate Zanubrutinib Combined With BR (Bendamustine/Rituximab) Regimen in Subjects With Newly-diagnosed Waldenström's Macroglobulinemia · 282 trials list this drug (72 active) | — | — | Waldenstrom Macroglobulinemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05934097Phase 1 · withdrawn FT596 in Combination With R-CHOP in Subjects With B-Cell Lymphoma · 282 trials list this drug (72 active) | — | — | Diffuse Large B-Cell Lymphoma,Follicular Lymphoma,Mantle Cell Lymphoma+1 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01754857Phase 2 · completed Bendamustine and Rituximab Induction Therapy and Maintenance Rituximab and Lenalidomide in Previously Untreated CLL/SLL · 282 trials list this drug (72 active) | — | — | Lymphoid Leukemia,Non-Hodgkin Lymphoma,Small Lymphocytic Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05899621recruiting A Real-world Study of Obinutuzumab-based Therapy for Previously Untreated FL · 282 trials list this drug (72 active) | — | — | Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01596621Phase 3 · completed A Study of Bendamustine in the Treatment of Chinese Participants With Indolent Non-Hodgkin Lymphoma Refractory to Rituximab Treatment · 282 trials list this drug (72 active) | — | — | Non-Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04268706Phase 2 · active not recruiting Phase 2 Study Evaluating Autologous CD30.CAR-T Cells in Patients With Relapsed/Refractory Hodgkin Lymphoma (CHARIOT) · 282 trials list this drug (72 active) | — | — | Hodgkin Lymphoma,Adult Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05352828Phase 1 · active not recruiting Autologous CD30.CAR-T in Combination With Nivolumab in cHL Patients After Failure of Frontline Therapy · 282 trials list this drug (72 active) | — | — | Classic Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03492775Phase 2 · completed First Line Therapy of Advanced Stage Follicular Lymphoma in Patients < 60 Years Not Eligible fo Standard Immunochemotherapy and in All Patients ≥ 60 Years · 282 trials list this drug (72 active) | — | — | Indolent Non-Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04236141Phase 3 · terminated A Study to Evaluate the Efficacy and Safety of Polatuzumab Vedotin in Combination With Bendamustine and Rituximab Compared With Bendamustine and Rituximab Alone in Chinese Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL). · 282 trials list this drug (72 active) | — | — | Diffuse Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02257242Phase 1 · completed Vincristine Sulfate Liposome Injection (Marqibo®), Bendamustine and Rituximab-Phase I Trial in Indolent B-cell Lymphoma · 282 trials list this drug (72 active) | — | — | Lymphoma,Non-Hodgkin Lymphoma,Follicular Lymphoma+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02257567Phase 1/Phase 2 · completed A Study of Polatuzumab Vedotin (DCDS4501A) in Combination With Rituximab or Obinutuzumab Plus Bendamustine in Participants With Relapsed or Refractory Follicular or Diffuse Large B-Cell Lymphoma · 282 trials list this drug (72 active) | — | — | Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01332968Phase 3 · completed A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM) · 282 trials list this drug (72 active) | — | — | Non-Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02793583Phase 2/Phase 3 · terminated Study to Assess the Efficacy and Safety of Ublituximab + Umbralisib With or Without Bendamustine and Umbralisib Alone in Patients With Previously Treated Non-Hodgkins Lymphoma · 282 trials list this drug (72 active) | — | — | Small Lymphocytic Lymphoma,Diffuse Large B-Cell Lymphoma,Follicular Lymphoma+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04138875Phase 2 · withdrawn A Risk Stratified Sequential Treatment With Rituximab, Brentuximab Vedotin and Bendamustine (RBvB) · 282 trials list this drug (72 active) | — | — | Lymphocytic Neoplasm,Polymorphic PTLD,Florid Follicular Hyperplasia PTLD+1 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04849715Phase 3 · withdrawn A Study of Parsaclisib, a PI3Kδ Inhibitor, in Combination With Bendamustine and Rituximab in Patients With Newly Diagnosed Mantle Cell Lymphoma · 282 trials list this drug (72 active) | — | — | Mantle Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04155840Phase 2 · terminated Bendamustine and Rituximab in Combination With Copanlisib for the Treatment of Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma · 282 trials list this drug (72 active) | — | — | Lymphoid Leukemia,Non-Hodgkin Lymphoma,Chronic Lymphocytic Leukemia+1 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00951457Phase 1/Phase 2 · completed Bendamustine Combined With Alemtuzumab in Pretreated Chronic Lymphocytic Leukemia (CLL) · 282 trials list this drug (72 active) | — | — | Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02954406Phase 1 · terminated A Study of TAK-659 in Combination With Bendamustine (+/-Rituximab), Gemcitabine, Lenalidomide, or Ibrutinib for the Treatment of Participants With Advanced Non-Hodgkin Lymphoma · 282 trials list this drug (72 active) | — | — | Non-Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02424851Phase 2 · completed Optimising Renal Outcome in Myeloma Renal Failure · 282 trials list this drug (72 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03914885no longer available Compassionate Use Re-Infusion of ATLCAR.CD30 · 282 trials list this drug (72 active) | — | — | Adult Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01535924Phase 1/Phase 2 · completed Gemcitabine and Bendamustine in Patients With Relapsed or Refractory Hodgkin's Lymphoma · 282 trials list this drug (72 active) | — | — | Adult Hodgkin Lymphoma,Adult Nodular Lymphocyte Predominant B-Cell Lymphoma,Adult Mixed Cellularity Classic Hodgkin Lymphoma+1 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01412879Phase 2 · completed S1106 Rituximab With Combination Chemotherapy or Bendamustine Hydrochloride Followed by Consolidation Chemotherapy and Stem Cell Transplantation in Older Patients With Previously Untreated Mantle Cell Lymphoma · 282 trials list this drug (72 active) | — | — | Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04882163Phase 1/Phase 2 · withdrawn Study to Evaluate Tolerability of Iberdomide (CC-220) in Combination With Polatuzumab Vedotin Plus Rituximab or Tafasitamab or Rituximab Plus Chemotherapy in B-cell Lymphoma · 282 trials list this drug (72 active) | — | — | B-Cell Malignant Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05006469Phase 3 · unknown Observation of the Efficacy of BAd Regimen in the Treatment of Relapsed and Refractory Multiple Myeloma · 282 trials list this drug (72 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01594229Phase 1 · completed A Study Evaluating the Safety and Pharmacokinetics of ABT-199 in Combination With Bendamustine/Rituximab (BR) in Subjects With Relapsed or Refractory Non-Hodgkin's Lymphoma · 282 trials list this drug (72 active) | — | — | Non-Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01188681Phase 1/Phase 2 · completed Safety and Efficacy Study of TRU-016 Plus Bendamustine vs. Bendamustine in Relapsed Chronic Lymphocytic Leukemia · 282 trials list this drug (72 active) | — | — | Chronic Lymphocytic Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03259529Phase 1/Phase 2 · completed Safety and Efficacy of Bendamustine, Gemcitabine, Rituximab, Nivolumab (BeGeRN) in Patients With r/r DLBCL · 282 trials list this drug (72 active) | — | — | Diffuse Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04913103Phase 2 · not yet recruiting Study of PV in Combination With Bendamustine and Rituximab for Patients With R/R MCL · 282 trials list this drug (72 active) | — | — | Mantle Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02499627Phase 2 · terminated Bendamustine Plus Brentuximab Vedotin in HL and CD30+ PTCL in First Salvage Setting · 282 trials list this drug (72 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02596971Phase 1/Phase 2 · completed A Study of Atezolizumab in Combination With Either Obinutuzumab Plus Bendamustine or Obinutuzumab Plus (+) Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) in Participants With Follicular Lymphoma (FL) or Rituximab + CHOP in Participants With Diffuse Large B-Cell Lymphoma (DLBCL) · 282 trials list this drug (72 active) | — | — | Diffuse Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01234766Phase 2 · completed Bendamustine and Rituximab Followed by 90-yttrium (Y) Ibritumomab Tiuxetan for Untreated Follicular Lymphoma · 282 trials list this drug (72 active) | — | — | Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02187133Phase 1 · completed Carfilzomib With Bendamustine and Rituximab in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma · 282 trials list this drug (72 active) | — | — | Lymphoma,Non-Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01088048Phase 1 · completed Study to Investigate Idelalisib in Combination With Chemotherapeutic Agents, Immunomodulatory Agents and Anti-CD20 Monoclonal Antibody (mAb) in Participants With Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma, Mantle Cell Lymphoma or Chronic Lymphocytic Leukemia · 282 trials list this drug (72 active) | — | — | Chronic Lymphocytic Leukemia,Indolent Non-Hodgkin Lymphoma,Mantle Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02576275Phase 3 · withdrawn A Study of Duvelisib in Combination With Rituximab and Bendamustine vs Placebo in Combination With Rituximab and Bendamustine in Subjects With Previously-Treated Indolent Non-Hodgkin Lymphoma (BRAVURA) · 282 trials list this drug (72 active) | — | — | Small Lymphocytic Lymphoma,Follicular Lymphoma,Indolent Non-Hodgkin Lymphoma+1 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02059239Phase 1/Phase 2 · completed Bendamustine Bridge to Autologous or Allogeneic Transplant for Relapsed/Refractory Lymphoma · 282 trials list this drug (72 active) | — | — | Hodgkin Lymphoma,Non-Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02414568Phase 2 · completed Bendamustine Study in Classical Hodgkin Lymphoma Patients Over 60 Treated by Prednisone, Vinblastine and Doxorubicin · 282 trials list this drug (72 active) | — | — | Classic Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04762745Phase 1/Phase 2 · unknown The Efficacy and Safety of Pomalidomide and Bendamustine With Dexamethasone in Relapsed or Refractory Multiple Myeloma · 282 trials list this drug (72 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02095834Phase 1 · completed Carfilzomib, Bendamustine Hydrochloride, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma · 282 trials list this drug (72 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02951156Phase 3 · terminated Avelumab In Combination Regimens That Include An Immune Agonist, Epigenetic Modulator, CD20 Antagonist and/or Conventional Chemotherapy in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL) · 282 trials list this drug (72 active) | — | — | Diffuse Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02799147Phase 1/Phase 2 · completed GVHD Prophylaxis With Post-transplantation Bendamustine in Refractory Leukemia · 282 trials list this drug (72 active) | — | — | Acute Lymphoblastic Leukemia,Acute Myeloid Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00389051Phase 1 · completed A Phase I Study of Bendamustine Hydrochloride in Patients With Indolent B-cell Non-Hodgkin's Lymphoma · 282 trials list this drug (72 active) | — | — | Non-Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02477215Phase 1/Phase 2 · completed Study of Bendamustine and IXAZOMIB (MLN9708) Plus Dexamethasone in Relapsed/Refractory Multiple Myeloma · 282 trials list this drug (72 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01671904Phase 1 · completed A Study of Venetoclax in Combination With Bendamustine + Rituximab or Bendamustine + Obinutuzumab in Participants With Relapsed/Refractory or Previously Untreated Chronic Lymphocytic Leukemia (CLL) · 282 trials list this drug (72 active) | — | — | Chronic Lymphocytic Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04569838Phase 2 · completed A Study to Evaluate the Efficacy and Safety of Bendamustine Hydrochloride Injection · 282 trials list this drug (72 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01889069Phase 3 · completed A Study to Evaluate Safety, Efficacy and Pharmacokinetics of Rituximab (MabThera/Rituxan) in Participants With Diffuse Large B Cell Lymphoma (DLBCL) or Follicular Lymphoma (FL) · 282 trials list this drug (72 active) | — | — | Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02689141Phase 2 · completed Sequential Regimen of Bendamustin-Debulking Followed by Ofatumumab and Ibrutinib in CLL Patients (CLL2-BIO) · 282 trials list this drug (72 active) | — | — | Chronic Lymphocytic Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03343652Phase 1/Phase 2 · completed A Study of Safety and Efficacy of Nivolumab and Bendamustine (NB) in Patients With Relapsed/Refractory Hodgkin's Lymphoma · 282 trials list this drug (72 active) | — | — | Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01490723Phase 2 · completed Zevalin-Containing Nonmyeloablative Conditioning for Stem Cell Transplantation (SCT) · 282 trials list this drug (72 active) | — | — | Leukemia,Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00901927Phase 2 · terminated Bendamustine, Mitoxantrone, and Rituximab (BMR) for Patients With Untreated High Risk Follicular Lymphoma · 282 trials list this drug (72 active) | — | — | Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01222260Phase 2 · completed Bendamustine and Dexamethasone in Patients With Relapsed AL Amyloidosis · 282 trials list this drug (72 active) | — | — | AL Amyloidosis | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01077518Phase 3 · terminated Ofatumumab Bendamustine Combination Compared With Bendamustine Monotherapy in Indolent B-cell NHL Unresponsive to Rituxtherapy · 282 trials list this drug (72 active) | — | — | Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04127916unknown Bendamustine Plus Rituximab for Mantle Cell Lymphoma: a Multicenter Retrospective Analysis(BR-MCL) · 282 trials list this drug (72 active) | — | — | Mantle Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01569295Phase 3 · completed Study Evaluating the Efficacy and Safety of Idelalisib in Combination With Bendamustine and Rituximab for Previously Treated Chronic Lymphocytic Leukemia (CLL) (Tugela ) · 282 trials list this drug (72 active) | — | — | Chronic Lymphocytic Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01611090Phase 3 · completed A Study of Ibrutinib in Combination With Bendamustine and Rituximab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma · 282 trials list this drug (72 active) | — | — | Chronic Lymphocytic Leukemia,Small Lymphocytic Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01049945Phase 1/Phase 2 · completed Bendamustine Hydrochloride, Lenalidomide, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma · 282 trials list this drug (72 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02320487Phase 2 · completed A Study of Obinutuzumab + Bendamustine (BG) in Participants With Previously Untreated Chronic Lymphocytic Leukemia (CLL) · 282 trials list this drug (72 active) | — | — | Chronic Lymphocytic Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02071225Phase 2 · completed A Study Evaluating the Efficacy of Obinutuzumab and Bendamustine Treatment in Participants With Refractory or Relapsed Chronic Lymphocytic Leukemia · 282 trials list this drug (72 active) | — | — | Chronic Lymphocytic Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00899431Phase 2 · terminated Nonmyeloablative Stem Cell Transplantation for Chronic Lymphocytic Leukemia (CLL) · 282 trials list this drug (72 active) | — | — | Chronic Lymphocytic Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01059630Phase 3 · completed A Study to Investigate the Efficacy and Safety of Bendamustine Compared With Bendamustine+Obinutuzumab (GA101) in Participants With Rituximab-Refractory, Indolent Non-Hodgkin's Lymphoma (GADOLIN) · 282 trials list this drug (72 active) | — | — | Non-Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01326702Phase 1/Phase 2 · completed Veliparib, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory Lymphoma, Multiple Myeloma, or Solid Tumors · 282 trials list this drug (72 active) | — | — | Adult Solid Neoplasm,Anaplastic Large Cell Lymphoma,Hairy Cell Leukemia+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00974233Phase 2 · completed Study of Bendamustine/Rituxan Induction Chemotherapy With Revlimid Maintenance for Relapsed/Refractory CLL and SLL · 282 trials list this drug (72 active) | — | — | Chronic Lymphocytic Leukemia,Small Lymphocytic Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01905943Phase 3 · completed A Safety and Efficacy Study of Obinutuzumab Alone or in Combination With Chemotherapy in Participants With Chronic Lymphocytic Leukemia · 282 trials list this drug (72 active) | — | — | Chronic Lymphocytic Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01429025Phase 1 · completed Rituximab, Bendamustine Hydrochloride, and Lenalidomide in Treating Patients With Refractory or Relapsed Indolent Non-Hodgkin Lymphoma · 282 trials list this drug (72 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01096992Phase 1/Phase 2 · completed Fludarabine, Bendamustine, and Rituximab (FBR) for Relapsed Chronic Lymphocytic Leukemia (CLL) · 282 trials list this drug (72 active) | — | — | Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02187861Phase 2 · completed A Study Evaluating the Safety and Efficacy of Venetoclax (GDC-0199) Plus Bendamustine + Rituximab (BR) in Comparison With BR or Venetoclax Plus Rituximab in Participants With Relapsed and Refractory Follicular Non-Hodgkin's Lymphoma (fNHL) · 282 trials list this drug (72 active) | — | — | Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00916058Phase 1/Phase 2 · completed Conditioning Regimen of Bendamustine and Melphalan Followed by Transplant in Patients With Multiple Myeloma · 282 trials list this drug (72 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00880815Phase 1 · completed Fludarabine, Bendamustine, and Rituximab in Treating Participants With Lymphoid Cancers Undergoing Stem Cell Transplant · 282 trials list this drug (72 active) | — | — | Chronic Lymphocytic Leukemia,T-Cell Non-Hodgkin Lymphoma,Diffuse Large B-Cell Lymphoma+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00274989Phase 2 · completed Bendamustine and Rituximab in Treating Patients With Previously Untreated or Relapsed Chronic Lymphocytic Leukemia · 282 trials list this drug (72 active) | — | — | Chronic Lymphocytic Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00987493Phase 1/Phase 2 · completed Rituximab, Bendamustine Hydrochloride, and Lenalidomide in Treating Patients With Aggressive B-Cell Lymphoma · 282 trials list this drug (72 active) | — | — | Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01874054Phase 1/Phase 2 · completed Study of Brentuximab Vedotin Combined With Bendamustine in Patients With Hodgkin Lymphoma · 282 trials list this drug (72 active) | — | — | Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01244451Phase 2 · completed GIMEMA CLL0809 Study (BendOfa) · 282 trials list this drug (72 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02240719Phase 1 · completed Everolimus and Bendamustine Hydrochloride in Treating Patients With Relapsed or Refractory Hematologic Cancer · 282 trials list this drug (72 active) | — | — | Multiple Myeloma,Adult Hodgkin Lymphoma,Chronic Lymphocytic Leukemia+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01165112Phase 1/Phase 2 · completed Bendamustine Hydrochloride, Rituximab, Etoposide, and Carboplatin in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma or Hodgkin Lymphoma · 282 trials list this drug (72 active) | — | — | Adult Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01980888Phase 3 · terminated Efficacy and Safety of Idelalisib in Combination With Bendamustine and Rituximab in Adults With Previously Untreated Chronic Lymphocytic Leukemia · 282 trials list this drug (72 active) | — | — | Chronic Lymphocytic Leukemia | 1 | Observed | clinicaltrials | graph → |